Product image of Myclausen (Mycophenolate Mofetil) supplied by GNH India

Myclausen

Active Ingredient:
Mycophenolate Mofetil
Origin:
EU

Myclausen (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Myclausen, is an antimetabolite immunosuppressant presented as an oral tablet for oral use. It is employed to prevent organ transplant rejection, treat lupus nephritis, and manage selected autoimmune diseases in adult patients.

GNH India supplies Myclausen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to EU GMP standards and provides reliable global distribution for clinical and commercial needs.

Manufacturer / TM Owner

Passauer Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Myclausen is an antimetabolite immunosuppressant used in conditions where immune modulation is required.
  • Organ transplant rejection: helps prevent immune‑mediated graft loss in kidney, heart, liver and other transplanted organs.
  • Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus affecting the kidneys.
  • Autoimmune diseases: suppresses abnormal immune activity in selected autoimmune disorders such as certain vasculitides.

How It Works

  • Mycophenolate Mofetil is converted intracellularly to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanine nucleotide synthesis, limiting DNA replication in activated T and B lymphocytes and thereby suppressing their proliferation and the overall immune response.

Side Effects

Myclausen may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, vomiting, diarrhoea.
  • Hematologic changes: leukopenia, anemia, thrombocytopenia.
  • Infections: increased susceptibility to bacterial, viral and fungal infections.
  • Headache and fatigue.
  • Elevated liver enzymes.

Serious or Rare Side Effects

  • Progressive multifocal leukoencephalopathy (PML).
  • Severe opportunistic infections such as cytomegalovirus disease.
  • Life‑threatening hypersensitivity reactions.
  • Renal impairment or acute kidney injury.
  • Malignancies, including lymphoproliferative disorders.

Precautions & Warnings

  • Before initiating Myclausen, clinicians should assess baseline laboratory values and monitor patients regularly.
  • Baseline labs: obtain complete blood count, liver and renal function tests.
  • Infection risk: screen for latent viral infections (e.g., CMV, EBV) and vaccinate appropriately before therapy.
  • Pregnancy: contraindicated; avoid use in women of childbearing potential unless effective contraception is used.
  • Drug interactions: review concomitant medications for potential additive immunosuppression.
  • Renal/hepatic impairment: adjust monitoring frequency in patients with organ dysfunction.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Myclausen can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Antimetabolites such as azathioprine: may cause excessive bone‑marrow suppression.
  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce mycophenolate exposure.
  • Live vaccines: increased risk of severe infection.

Moderate Interactions (Monitor Closely)

  • Antacids containing magnesium or aluminum: may decrease absorption; separate dosing by at least 2 hours.
  • ACE inhibitors or ARBs: monitor renal function and potassium levels.
  • Concomitant nephrotoxic agents (e.g., calcineurin inhibitors): watch for additive renal toxicity.

Frequently Asked Questions

Myclausen contains mycophenolate mofetil and is prescribed to prevent rejection of transplanted organs, to treat lupus nephritis, and to manage certain autoimmune disorders where suppression of the immune system is required.

After oral administration, mycophenolate mofetil is converted to mycophenolic acid, which selectively blocks inosine monophosphate dehydrogenase. This inhibition reduces guanine nucleotide synthesis, limiting DNA replication in activated lymphocytes and thereby dampening the immune response.

The dosage of Myclausen is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and concomitant therapies. Patients should follow the dose and schedule provided by their healthcare professional.

Myclausen is classified as Pregnancy Category X, indicating it is contraindicated during pregnancy because of a high risk of fetal harm. It is also not recommended while breastfeeding, as the drug can be excreted in milk and affect the infant.

To order Myclausen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to mycophenolate mofetil is azathioprine, another antimetabolite. Myclausen generally offers more potent inhibition of lymphocyte proliferation with a different side‑effect profile, but both require careful monitoring for bone‑marrow suppression and infection risk.

Myclausen should be stored at ambient temperature, below 25 °C, in its original container. Protect the tablets from moisture, heat and direct sunlight. Do not refrigerate or freeze the product.

Myclausen is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The tablets should be swallowed whole; they are not intended for crushing, chewing, or sublingual administration.

Serious risks include life‑threatening infections, progressive multifocal leukoencephalopathy, severe hypersensitivity reactions, and increased incidence of certain malignancies. Patients should be monitored closely for signs of infection, neurological changes, or unexplained skin reactions.

Myclausen is contraindicated in individuals with known hypersensitivity to mycophenolate mofetil or any excipients, in pregnant women, and in patients with uncontrolled infections. Caution is also advised for those with severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolate Mofetil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT